Ductal carcinoma in situ

From Citizendium
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

In oncology, ductal carcinoma in situ (DCIS), also called noninfiltrating intraductal carcinoma, is "a noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma."[1]

The importance of DCIS is not clear..[2] However, it may benefit from treatment.[3]

References

  1. Anonymous (2024), Ductal carcinoma in situ (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G et al. (2009). "Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms.". Ann Intern Med 151 (10): 738-47. DOI:10.1059/0003-4819-151-10-200911170-00010. PMID 19920274. Research Blogging.
  3. Cuzick, Jack; Ivana Sestak, Sarah E Pinder, Ian O Ellis, Sharon Forsyth, Nigel J Bundred, John F Forbes, Hugh Bishop, Ian S Fentiman, William D George (2010). "Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial". The Lancet Oncology. DOI:10.1016/S1470-2045(10)70266-7. ISSN 14702045. Retrieved on 2010-12-08. Research Blogging.